Expertise in
47
conditions

Dr. Donald Jurgens

Hematology | Oncology
Centracare Coborn Cancer Center
1900 Centracare Cir, Ste 1600, 
Saint Cloud, MN 
Expertise in
47
conditions
Centracare Coborn Cancer Center
1900 Centracare Cir, Ste 1600, 
Saint Cloud, MN 

Overview

Donald Jurgens is a Hematologist and an Oncologist practicing medicine in Saint Cloud, Minnesota.

Dr. Jurgens is highly rated in 47 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Urothelial Cancer, Small Cell Lung Cancer (SCLC), Bone Marrow Aspiration, and Prostatectomy.

Dr. Jurgens is board certified in American Board Of Internal Medicine - Medical Oncology. He is actively involved in clinical research, participating in 76 clinical trials.

Graduate Institution

University Of Minnesota Medical School

Residency

Mayo Clinic School of Graduate Medical Education, Medicine

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MN

Board Certifications

American Board Of Internal Medicine - Medical Oncology

Fellowships

Mayo Clinic School of Graduate Medical Education, Hematology/Oncology

Hospital Affiliations

Centracare - St. Cloud Hospital
Centracare Health System - Melrose Hospital
St Gabriels Hospital
Astera Health
Centracare - Paynesville Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Sanford Health
  • HMO
  • PPO
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Centracare Coborn Cancer Center
1900 Centracare Cir, Ste 1600, Saint Cloud, MN 56303
Other Locations
CentraCare - Coborn Cancer Center
1900 CentraCare Cir, Ste 1600, St Cloud, MN 56303
Astera Health / CentraCare Coborn Cancer Center
421 11th St NW, Wadena, MN 56482

Additional Areas of Focus

Dr. Jurgens has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

75 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
5
conditions
Dr. Gordon J. Ruan
Oncology | Hematology
Expertise in
5
conditions
Dr. Gordon J. Ruan
Oncology | Hematology
Referral may be required

HealthPartners Frauenshuh Cancer Center

3931 Louisiana Ave, 
S Saint Louis Park, MN 
 (59.2 miles away)
612-341-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

As a doctor who diagnoses and treats cancer, medicine is a calling for me. I strive to always provide the highest quality of care to my patients. I strongly believe that every patient needs to be treated as a whole, and it is critical for me to understand each and every one of my patients’ backgrounds and needs. I also have a strong interest in clinical trials. There have been many exciting therapies in the field of hematology/oncology – the field of medicine focusing on cancer diagnosis and treatment. But more research still needs to be done to keep improving upon the standard of care. Dr. Ruan is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Reticulohistiocytoma, Histiocytosis, Rosai-Dorfman Disease, Non-Langerhans-Cell Histiocytosis, and Bone Marrow Aspiration. Dr. Ruan is board certified in American Board Of Internal Medicine-Medical Oncology, American Board Of Internal Medicine-Hematology, and American Board Of Internal Medicine. Dr. Ruan is currently accepting new patients.

Expertise in
61
conditions
Dr. Joseph Levine
Hematology | Oncology
Expertise in
61
conditions
Dr. Joseph Levine
Hematology | Oncology
Referral may be required

Monticello Cancer Center

1001 Hart Blvd, Ste 50, 
Monticello, MN 
 (28.4 miles away)
763-271-2800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Levine is a Hematologist and an Oncologist practicing medicine in Monticello, Minnesota. Dr. Levine is highly rated in 61 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Levine is board certified in American Board Of Internal Medicine - Hematology, American Board Of Internal Medicine - Medical Oncology, and American Board Of Internal Medicine - Internal Medicine.

Expertise in
68
conditions
Expertise in
68
conditions
Referral may be required

CentraCare - Coborn Cancer Center

1900 CentraCare Cir, Ste 1600, 
St Cloud, MN 
 (0.1 miles away)
320-229-4900
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Hani Alkhatib is an Oncologist practicing medicine in St Cloud, Minnesota. Dr. Alkhatib is highly rated in 68 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Hairy Cell Leukemia (HCL), Familial Colorectal Cancer, Bone Marrow Aspiration, and Gastrostomy. Dr. Alkhatib is board certified in American Board Of Internal Medicine - Medical Oncology and American Board Of Internal Medicine - Internal Medicine. Dr. Alkhatib is currently accepting new patients.

Frequently Asked Questions about Dr. Donald Jurgens

How do I make an appointment with Dr. Donald Jurgens?

You can book an appointment with Dr. Donald Jurgens by calling their office at 320-229-4900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Donald Jurgens a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Donald Jurgens is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Donald Jurgens specialize in?

While Dr. Donald Jurgens is a Hematology, they have specific expertise in Lung Cancer, Urothelial Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Donald Jurgens accept my insurance?

Dr. Donald Jurgens accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 320-229-4900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jurgens's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 39 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile